(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.

@article{Benz201118FFDGPF,
  title={(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.},
  author={Matthias R Benz and Ken Herrmann and Franziska Walter and Edward B. Garon and Karen L Reckamp and Robert Alan Figlin and Michael E. Phelps and Wolfgang Weber and Johannes G Czernin and Martin S. Allen-Auerbach},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2011},
  volume={52 11},
  pages={1684-1689}
}
UNLABELLED Response rates of unselected non-small cell lung cancer (NSCLC) patients to the epidermal growth factor receptor inhibitor erlotinib are low and range from 10% to 20%. Early response assessments are needed to avoid costs and side effects of inefficient treatments. Here we determined whether early changes in tumor uptake of (18)F-FDG can predict progression-free and overall survival in NSCLC patients who are treated with erlotinib. METHODS Twenty-two patients (6 men, 16 women; mean… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…